196 related articles for article (PubMed ID: 12019103)
1. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis.
Yoshimatsu T; Nuermberger E; Tyagi S; Chaisson R; Bishai W; Grosset J
Antimicrob Agents Chemother; 2002 Jun; 46(6):1875-9. PubMed ID: 12019103
[TBL] [Abstract][Full Text] [Related]
2. In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis.
Almeida D; Nuermberger E; Tyagi S; Bishai WR; Grosset J
Antimicrob Agents Chemother; 2007 Dec; 51(12):4261-6. PubMed ID: 17938193
[TBL] [Abstract][Full Text] [Related]
3. Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice.
Veziris N; Lounis N; Chauffour A; Truffot-Pernot C; Jarlier V
Antimicrob Agents Chemother; 2005 Oct; 49(10):4015-9. PubMed ID: 16189074
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice.
Lounis N; Bentoucha A; Truffot-Pernot C; Ji B; O'Brien RJ; Vernon A; Roscigno G; Grosset J
Antimicrob Agents Chemother; 2001 Dec; 45(12):3482-6. PubMed ID: 11709328
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.
Ji B; Lounis N; Maslo C; Truffot-Pernot C; Bonnafous P; Grosset J
Antimicrob Agents Chemother; 1998 Aug; 42(8):2066-9. PubMed ID: 9687408
[TBL] [Abstract][Full Text] [Related]
6. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis.
Miyazaki E; Miyazaki M; Chen JM; Chaisson RE; Bishai WR
Antimicrob Agents Chemother; 1999 Jan; 43(1):85-9. PubMed ID: 9869570
[TBL] [Abstract][Full Text] [Related]
7. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.
Rosenthal IM; Zhang M; Williams KN; Peloquin CA; Tyagi S; Vernon AA; Bishai WR; Chaisson RE; Grosset JH; Nuermberger EL
PLoS Med; 2007 Dec; 4(12):e344. PubMed ID: 18092886
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis.
Alvirez-Freites EJ; Carter JL; Cynamon MH
Antimicrob Agents Chemother; 2002 Apr; 46(4):1022-5. PubMed ID: 11897584
[TBL] [Abstract][Full Text] [Related]
9. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
Shandil RK; Jayaram R; Kaur P; Gaonkar S; Suresh BL; Mahesh BN; Jayashree R; Nandi V; Bharath S; Balasubramanian V
Antimicrob Agents Chemother; 2007 Feb; 51(2):576-82. PubMed ID: 17145798
[TBL] [Abstract][Full Text] [Related]
10. Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis.
Rosenthal IM; Williams K; Tyagi S; Vernon AA; Peloquin CA; Bishai WR; Grosset JH; Nuermberger EL
Am J Respir Crit Care Med; 2005 Dec; 172(11):1457-62. PubMed ID: 16141439
[TBL] [Abstract][Full Text] [Related]
11. Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.
Nuermberger E; Tyagi S; Williams KN; Rosenthal I; Bishai WR; Grosset JH
Am J Respir Crit Care Med; 2005 Dec; 172(11):1452-6. PubMed ID: 16151038
[TBL] [Abstract][Full Text] [Related]
12. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis.
Ibrahim M; Andries K; Lounis N; Chauffour A; Truffot-Pernot C; Jarlier V; Veziris N
Antimicrob Agents Chemother; 2007 Mar; 51(3):1011-5. PubMed ID: 17178794
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans.
Ji B; Lefrançois S; Robert J; Chauffour A; Truffot C; Jarlier V
Antimicrob Agents Chemother; 2006 Jun; 50(6):1921-6. PubMed ID: 16723546
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis.
Rouan MC; Lounis N; Gevers T; Dillen L; Gilissen R; Raoof A; Andries K
Antimicrob Agents Chemother; 2012 Mar; 56(3):1444-51. PubMed ID: 22155815
[TBL] [Abstract][Full Text] [Related]
15. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study.
Pletz MW; De Roux A; Roth A; Neumann KH; Mauch H; Lode H
Antimicrob Agents Chemother; 2004 Mar; 48(3):780-2. PubMed ID: 14982764
[TBL] [Abstract][Full Text] [Related]
16. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration.
Lounis N; Veziris N; Chauffour A; Truffot-Pernot C; Andries K; Jarlier V
Antimicrob Agents Chemother; 2006 Nov; 50(11):3543-7. PubMed ID: 16954317
[TBL] [Abstract][Full Text] [Related]
17. Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis.
Nikonenko BV; Samala R; Einck L; Nacy CA
Antimicrob Agents Chemother; 2004 Dec; 48(12):4550-5. PubMed ID: 15561824
[TBL] [Abstract][Full Text] [Related]
18. Bactericidal activity of moxifloxacin on exponential and stationary phase cultures of Mycobacterium tuberculosis.
Sulochana S; Mitchison DA; Kubendiren G; Venkatesan P; Paramasivan CN
J Chemother; 2009 Apr; 21(2):127-34. PubMed ID: 19423464
[TBL] [Abstract][Full Text] [Related]
19. Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis.
Kubendiran G; Paramasivan CN; Sulochana S; Mitchison DA
J Chemother; 2006 Dec; 18(6):617-23. PubMed ID: 17267339
[TBL] [Abstract][Full Text] [Related]
20. Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo.
Veziris N; Truffot-Pernot C; Aubry A; Jarlier V; Lounis N
Antimicrob Agents Chemother; 2003 Oct; 47(10):3117-22. PubMed ID: 14506018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
